Theron Pharmaceuticals is a late pre‐clinical stage company developing a best‐in‐class bronchodilator for respiratory diseases, including the multi‐billion dollar chronic obstructive pulmonary diseases (COPD) market. Theron has identified several development candidates that have potency, efficacy and long duration of bronchoprotection comparable to tiotropium in guinea pigs and dogs with a rapid onset of action.